Physician profile
Timothy A Wright
NPI 1619405669
$1,755.63
in general payments reported to CMS, 2019-2025
14 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $37.53 · 2023: $190 · 2024: $250 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.36 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $304.95 | 2023-2025 | |
| Abbott Laboratories | $237.11 | 2023-2025 | Cardiomems, Aveir |
| E.R. Squibb & Sons, L.L.C. | $209.63 | 2022-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $204.64 | 2025 | |
| Novartis Pharmaceuticals Corporation | $182.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $170.16 | 2021-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.28 | 2021-2025 | Jardiance |
| Bridgebio Pharma, INC. | $64.82 | 2025 | Attruby |
| Amgen INC. | $54.05 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $48.56 | 2023-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $48.18 | 2025 | Opsumit, Uptravi |
| Novo Nordisk INC | $24.21 | 2024 | Rybelsus, Ozempic |
| Baxter Healthcare | $23.09 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $20.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.